Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer.

International journal of medical sciences - 1 Jan 2026

Wei Po-Li, Huang Chien-Yu, Lee Cheng-Chin, Batzorig Uyanga, Tsai Kuei-Yen, Chang Yu-Jia

Abstract excerpt

Background: Chemoresistance remains a major limitation in the treatment of colorectal cancer (CRC), particularly in tumors harboring TP53 mutations. Although aldehyde dehydrogenase 2 (ALDH2) has been implicated in cancer biology, its role in regulating platinum sensitivity and the underlying molecular context remain incompletely understood. Methods: Public transcriptomic and proteomic datasets (TCGA, GEO, CPTAC)...

Read the complete abstract on PubMed

Topics

Humans
Oxaliplatin
Colorectal Neoplasms
Drug Resistance, Neoplasm
Aldehyde Dehydrogenase, Mitochondrial
Tumor Suppressor Protein p53

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Cyclic Nucleotide Phosphodiesterases, Type 4

Gene Expression Regulation, Neoplastic

Cell Line, Tumor

Mutation

Apoptosis

Antineoplastic Agents

Female

Source

Open in PubMed Open full text

Identifiers

PMID: 42694559
DOI: 10.7150/ijms.133461
PMCID: PMC13539918

Genes

ALDH2
PDE4B
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer.PMID 42694559Read ↗

Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancerSemantic proximity Read ↗

Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell linesSemantic proximity Read ↗

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancerSemantic proximity Read ↗

Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-FluorouracilSemantic proximity Read ↗

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cellsSemantic proximity Read ↗

Functional Genomics Reveals Diverse Cellular Processes That Modulate Tumor Cell Response to OxaliplatinSemantic proximity Read ↗

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell LinesSemantic proximity Read ↗

Cyclophilin B induces chemoresistance by degrading wild‐type p53 via interaction with MDM2 in colorectal cancerSemantic proximity Read ↗

FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expressionSemantic proximity Read ↗

USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancerSemantic proximity Read ↗

HMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancerSemantic proximity Read ↗

CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.